About this episode

Dr. Ghassan K. Abou-Alfa discusses the findings of the EMERALD-3 study on treatment options for patients with unresectable liver cancers presented at ASCO 2026.

CHICAGO, USA—Patients with unresectable liver cancers who were eligible for treatment with transarterial chemoembolization (TACE), were randomly offered, treatment with the anti-CTL-4 checkpoint inhibitor tremelimumab together with the anti PD-L1 inhibitor durvalumab with or without a third drug: the multiple VEGFR 1, 2 & 3 kinase inhibitor, lenvatinib, in the phase threeEMERALD-3 study. Findings of a significant improvement of progression free survival were reported at the 2026 American Society of Clinical Oncology Annual Meeting by first author Ghassan Abou-Alfa MD PhD from the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, in New York and Weill Medical College, Cornell University, New York, NY. After his talk in Chicago Dr. Abou-Alfa gave Peter Goodwin the details:

People in this episode

Host: Peter Goodwin

Guest: Ghassan K. Abou-Alfa MD PhD

Topics covered

• Hepatocellular Cancer
• Immune Checkpoint Inhibition
• Transarterial Chemoembolization
• Progression Free Survival
• ASCO 2026
• Clinical Trials

Keywords

• Hepatocellular Cancer
• immune checkpoint inhibitors
• progression free survival
• transarterial chemoembolization
• ASCO 2026
• clinical oncology
• VEGFR inhibitors

Mentioned in this episode

Organizations: Memorial Sloan Kettering Cancer Center, Weill Medical College, Cornell University

Products: tremelimumab, durvalumab, lenvatinib

Places: Chicago, USA

More episodes of Audio Journal of Oncology Podcast

• Kevin Kalinsky MD; ASCO 2026: ASCENT-04 Study Finds Sacituzumab Govitecan plus Pembrolizumab Helps Patients with Previously Untreated Metastatic PD-L1 Positive Triple Negative Breast Cancer Live Longer Without Progression Beyond Subsequent Therapies · July 14, 2026 · 8 min
• Wing-Lok Chan MBBS; 2026 ASCO: Patients with Advanced Cancer Using The SUPPORT+ Mobile Phone App With Nurse Supervision have Better Quality of Life and Fewer Hospitalizations · July 8, 2026 · 9 min
• Jonathan W. Goldman MD and David R Spigel MD; ASCO 2026: Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results · June 23, 2026 · 10 min
• Mark A Dickson, ASCO 2026: Abemaciclib Brings Marked Increase in Progression Free Survival for Patients with Advanced Dedifferentiated Liposarcoma · June 15, 2026 · 7 min
• Jana de Boniface MD PhD; ASCO 2026: Omitting Axillary Lymph Node Dissection is Safe for Patients with Breast Cancer Macrometastases to One or Two Sentinel Lymph Nodes · June 11, 2026 · 7 min
• Jean-Marc Classe, MD PhD; ASCO 2026: Timing of Surgery for Advanced Ovarian Cancer among Neoadjuvant and Adjuvant Chemotherapy Cycles: Early Findings from Randomized CHRONO Trial · June 9, 2026 · 9 min

Explore listener stats, chart rankings, contacts and more on the Audio Journal of Oncology Podcast podcast page.